Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome.

Ravassa S, López B, Querejeta R, Echegaray K, San José G, Moreno MU, Beaumont FJ, González A, Díez J.

J Hypertens. 2017 Apr;35(4):853-861. doi: 10.1097/HJH.0000000000001258.

PMID:
28253222
2.

Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure.

Echegaray K, Andreu I, Lazkano A, Villanueva I, Sáenz A, Elizalde MR, Echeverría T, López B, Garro A, González A, Zubillaga E, Solla I, Sanz I, González J, Elósegui-Artola A, Roca-Cusachs P, Díez J, Ravassa S, Querejeta R.

Rev Esp Cardiol (Engl Ed). 2017 Oct;70(10):832-840. doi: 10.1016/j.rec.2016.12.038. Epub 2017 Feb 16. English, Spanish.

PMID:
28215921
3.

Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure.

López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J.

J Am Coll Cardiol. 2016 Jan 26;67(3):251-60. doi: 10.1016/j.jacc.2015.10.063.

4.

Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism.

Huerta A, López B, Ravassa S, San José G, Querejeta R, Beloqui Ó, Zubillaga E, Rábago G, Brugnolaro C, Díez J, González A.

J Hypertens. 2016 Jan;34(1):130-8. doi: 10.1097/HJH.0000000000000757.

PMID:
26575701
5.

Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal.

López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R, Díez J.

J Am Coll Cardiol. 2015 Jun 9;65(22):2449-56. doi: 10.1016/j.jacc.2015.04.026. Review.

6.

Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.

López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J.

Eur J Heart Fail. 2015 Apr;17(4):385-92. doi: 10.1002/ejhf.246. Epub 2015 Feb 11.

7.

Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure.

López B, González A, Querejeta R, Larman M, Rábago G, Díez J.

Hypertension. 2014 Mar;63(3):483-9. doi: 10.1161/HYPERTENSIONAHA.113.02654. Epub 2013 Dec 23.

PMID:
24366078
8.

Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?

López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, Larman M, Tschöpe C, Díez J.

Cardiovasc Res. 2013 Jul 1;99(1):111-20. doi: 10.1093/cvr/cvt100. Epub 2013 Apr 25.

PMID:
23619422
9.

Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase.

López B, Querejeta R, González A, Larman M, Díez J.

Hypertension. 2012 Sep;60(3):677-83. doi: 10.1161/HYPERTENSIONAHA.112.196113. Epub 2012 Jul 23.

PMID:
22824984
10.

Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction.

González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J.

Hypertension. 2010 Jun;55(6):1418-24. doi: 10.1161/HYPERTENSIONAHA.109.149112. Epub 2010 Apr 19.

11.

Phospholipase Cbeta4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes.

Otaegui D, Querejeta R, Arrieta A, Lazkano A, Bidaurrazaga A, Arriandiaga JR, Aldazabal P, Garro MA.

Mol Cell Biochem. 2010 Apr;337(1-2):167-73. doi: 10.1007/s11010-009-0296-x. Epub 2009 Oct 24.

PMID:
19856080
12.

Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications.

López B, González A, Querejeta R, Barba J, Díez J.

J Hypertens. 2009 Feb;27(2):418-24. doi: 10.1097/HJH.0b013e32831ac981.

13.

Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure.

López B, Querejeta R, González A, Beaumont J, Larman M, Díez J.

Hypertension. 2009 Feb;53(2):236-42. doi: 10.1161/HYPERTENSIONAHA.108.125278. Epub 2008 Dec 15.

14.

Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure.

González A, Ravassa S, Loperena I, López B, Beaumont J, Querejeta R, Larman M, Díez J.

J Hypertens. 2007 Oct;25(10):2148-57.

15.

Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction.

Ravassa S, González A, López B, Beaumont J, Querejeta R, Larman M, Díez J.

Eur Heart J. 2007 Nov;28(22):2785-91. Epub 2007 Aug 31.

16.

Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.

López B, González A, Beaumont J, Querejeta R, Larman M, Díez J.

J Am Coll Cardiol. 2007 Aug 28;50(9):859-67. Epub 2007 Aug 13.

17.

[Altered fibrillar collagen metabolism in hypertensive heart failure. Current understanding and future prospects].

López Salazar B, Ravassa Albéniz S, Arias Guedón T, González Miqueo A, Querejeta R, Díez Martínez J.

Rev Esp Cardiol. 2006 Oct;59(10):1047-57. Review. Spanish.

18.

Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure.

López B, González A, Querejeta R, Larman M, Díez J.

J Am Coll Cardiol. 2006 Jul 4;48(1):89-96. Epub 2006 Jun 12.

19.

Apoptosis in hypertensive heart disease: a clinical approach.

González A, Ravassa S, López B, Loperena I, Querejeta R, Díez J.

Curr Opin Cardiol. 2006 Jul;21(4):288-94.

20.

Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease.

Goikoetxea MJ, Beaumont J, González A, López B, Querejeta R, Larman M, Díez J.

Cardiovasc Res. 2006 Mar 1;69(4):899-907. Epub 2005 Dec 20.

Supplemental Content

Loading ...
Support Center